Ride the Momentum
Announced that six COVID-19 patients treated with mavrilimumab in Italy all responded to treatment, and 3 patients were discharged within 5 days.
A follow-on controlled study in Italy is planned. Shares closed the week up 43% to $17.91.
- BioPharmCatalyst
Breaking through the recent top will be a strong indicator for further upside movement.
Hovering aorund the recent top without a follow through could indicate not enough buying power and distribution is taking place and a strong move in the downside direction could occur.
Take the potential support levels with a grain of salt as there is only 52.23M Shares Outstanding and a share float of 18.79M.
Short Float is currently 7.19%
Consensus Analyst Profit Target = 25.50$ according to MarketBeat
Most recent: 4/1/2020 Bank of America 25$
A follow-on controlled study in Italy is planned. Shares closed the week up 43% to $17.91.
- BioPharmCatalyst
Breaking through the recent top will be a strong indicator for further upside movement.
Hovering aorund the recent top without a follow through could indicate not enough buying power and distribution is taking place and a strong move in the downside direction could occur.
Take the potential support levels with a grain of salt as there is only 52.23M Shares Outstanding and a share float of 18.79M.
Short Float is currently 7.19%
Consensus Analyst Profit Target = 25.50$ according to MarketBeat
Most recent: 4/1/2020 Bank of America 25$
Thông báo miễn trừ trách nhiệm
Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.